A Study of Indinavir Sulfate Given Together With Stavudine to HIV-Positive Patients

Inclusion Criteria Concurrent Medication: Allowed: * Prophylaxis with aerosolized pentamidine, topical antifungals, TMP / SMX, dapsone, or isoniazid. Patients must have: * HIV infection. * CD4 count 50 - 500 cells/mm3. * Prior AZT use for more than 6 months OR documented intolerance to AZT with more than 6 months use of another anti-HIV therapy other than d4T or any protease inhibitor. * No active opportunistic infection or visceral Kaposi's sarcoma. NOTE: * Patients with hemophilia may be enrolled at discretion of investigator. Exclusion Criteria Co-existing Condition: Patients with the following symptoms or conditions are excluded: * Symptomatic neuropathy. * Acute hepatitis. Concurrent Medication: Excluded: * Antiretrovirals other than specified in protocol. * Chronic therapy for an active opportunistic infection. * Immunosuppressive therapy. Prior Medication: Excluded: * Any prior protease inhibitor or d4T. * Any nucleoside analogs within 2 weeks prior to study entry. * Investigational agents or immunomodulators within 30 days prior to study entry. Required: * More than 6 months of prior AZT unless intolerant, in which case more than 6 months of another anti-HIV therapy (other than protease inhibitors or d4T).